News

Inaticabtagene Autoleucel Demonstrates Efficacy and Tolerability for Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia

03/25/2025

Emily Estrada

Inaticabtagene autoleucel treatment for patients with relapsed/refractory B-cell acute lymphoblastic leukemia showed efficacy and durability in a phase 2 clinical trial.

Inaticabtagene autoleucel...

03/25/2025

Oncology

News

Durability and Tolerability of Obecabtagene Autoleucel CAR-T Therapy for R/R B-Cell Acute Lymphoblastic Leukemia

02/07/2025

Emily Estrada

For patients with relapsed/refractory B-cell acute lymphoblastic leukemia, obecabtagene autoleucel anti-CD19 CAR-T therapy showed promising durability and tolerability, according to a recent study.

For patients with...

02/07/2025

Oncology

News

FDA Approves Oral Formulation of Imatinib for Patients With Certain Leukemias and Gastrointestinal Tumors

11/25/2024

Stephanie Holland

The FDA has approved an advanced liquid formulation of imatinib for patients with certain leukemias and gastrointestinal tumors to increase dosing accuracy.

The FDA has approved an advanced...

11/25/2024

Oncology

FDA Approval

FDA Grants Approval to Obecabtagene Autoleucel for R/R B-Cell Precursor Acute Lymphoblastic Leukemia

11/08/2024

On November 8, 2024, the FDA approved CD19-directed genetically modified autologous T cell immunotherapy obecabtagene autoleucel for the treatment of patients with relapsed/refractory B-cell precursor acute lymphoblastic leukemia.

On November 8, 2024, the FDA...

11/08/2024

Oncology

News

Blinatumomab Added to Consolidation Chemotherapy Improves Overall Survival Among Patients in MRD-Negative Remission From B-Cell Precursor ALL

08/14/2024

Amber Denham

According to a phase 3 study, the addition of blinatumomab to consolidation chemotherapy for adult patients in measurable residual disease-negative remission from B-cell precursor acute lymphoblastic leukemia significantly improved overall...

According to a phase 3 study,...

08/14/2024

Oncology

News

FDA Grants Approval to Blinatumomab Consolidation Therapy for CD19-Positive Philadelphia Chromosome-Negative B-cell Precursor ALL

06/21/2024

The FDA granted approval to blinatumomab for adult and pediatric patients with CD19-positive Philadelphia chromosome-negative B-cell precursor acute lymphoblastic leukemia (ALL) in the consolidation phase of multi-phase chemotherapy.

The FDA granted approval to...

06/21/2024

Oncology

News

Mini-Hyper-CVD Plus Venetoclax Yields Safety and Activity Among Patients With Heavily Pretreated R/R ALL

04/09/2024

Jordan Kadish

According to a phase 1/2 trial, combining mini-hyper-CVD low-intensity chemotherapy with venetoclax yielded safety and activity among patients with heavily pretreated R/R acute lymphoblastic leukemia.

According to a phase 1/2 trial,...

04/09/2024

Oncology

News

Allogeneic Stem Cell Transplantation in First Complete Remission for Patients With Philadelphia Chromosome-Positive ALL

04/01/2024

Jordan Kadish

Patients with Philadelphia chromosome-positive acute lymphoblastic leukemia who received allogeneic stem cell transplantation in the first complete remission demonstrated superior survival outcomes compared with patients who did not undergo...

Patients with Philadelphia...

04/01/2024

Oncology

FDA Approval

FDA Approves Ponatinib With Chemotherapy for Patients With Newly-Diagnosed Ph-Positive Acute Lymphoblastic Leukemia

03/21/2024

Jordan Kadish

On March 19, 2024, the US FDA granted accelerated approval to ponatinib with chemotherapy for patients with newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia.

On March 19, 2024, the US FDA...

03/21/2024

Oncology

News

Imatinib vs Dasatinib Prophylaxis Among Patients With Philadelphia-Positive ALL Post-Transplantation

03/15/2024

Jordan Kadish

Imatinib prophylaxis demonstrated outcomes comparable to dasatinib among patients with Philadelphia-positive acute lymphoblastic leukemia after allogeneic stem cell transplantation at first complete remission, according to a retrospective...

Imatinib prophylaxis...

03/15/2024

Oncology

Recent News

News

Modakafusp Alfa Demonstrates Antitumor Activity Among Patients With Relapsed/Refractory Multiple Myeloma

04/02/2025

Emily Estrada

At a tolerable and safe dose, the anti-CD38 antibody, modakafusp alfa demonstrated decreased tumor activity and immune activation among patients with relapsed/refractory multiple myeloma.

At a tolerable and safe dose,...

04/02/2025

Oncology

News

Quadruplet Therapy Demonstrates Efficacy for Treatment of Transplant-Ineligible Newly Diagnosed Multiple Myeloma

04/02/2025

Emily Estrada

Quadruplet therapy with isatuximab, weekly bortezomib, lenalidomide, and limited dexamethasone demonstrated safety and efficacy for older patients with transplant-ineligible MM in a phase 2 clinical trial.

Quadruplet therapy with...

04/02/2025

Oncology

News

Co-Occurrence of High-Risk Cytogenetic Abnormalities as a Predictive Marker for Multiple Myeloma

04/02/2025

Emily Estrada

The presence of 2 or more high-risk cytogenetic abnormalities among patients with multiple myeloma was associated with poor survival outcomes, according to a systematic review and meta-analysis.

The presence of 2 or more...

04/02/2025

Oncology

News

Pembrolizumab Plus Bevacizumab Shows Promise Among Previously Untreated Patients With Melanoma Brain Metastases

04/01/2025

Stephanie Holland

According to results from a phase 2 study, pembrolizumab plus bevacizumab demonstrated promise among previously untreated patients with melanoma brain metastases.

According to results from a...

04/01/2025

Oncology

News

Outcomes Without Adjuvant Radioactive Iodine Among Pediatric Patients With Papillary Thyroid Cancer

04/01/2025

Allison Casey

According to a retrospective cohort study, omitting adjuvant radioactive iodine therapy for pediatric patients with papillary thyroid cancer did not compromise outcomes.

According to a retrospective...

04/01/2025

Oncology

News

Lenvatinib Plus High-Dose Radioiodine Therapy Shows Promise for Patients With Metastatic Well-Differentiated Thyroid Cancer

04/01/2025

Allison Casey

A study found the addition of lenvatinib to high-dose radioiodine therapy showed promise in improving response for patients with metastatic well-differentiated radioiodine-avid thyroid cancer.

A study found the addition of...

04/01/2025

Oncology

News

Zenocutuzumab Demonstrates Durable Activity in NRG1 Fusion–Positive Solid Tumors

03/31/2025

Janelle Bradley

Findings from a phase 2 study show zenocutuzumab demonstrated durable clinical activity and a favorable safety profile in patients with NRG1 fusion–positive solid tumors, particularly non–small-cell lung and pancreatic cancers.

Findings from a phase 2 study...

03/31/2025

Oncology

FDA Approval

Durvalumab Approved for Muscle Invasive Bladder Cancer

03/31/2025

Allison Casey

The US FDA approved neoadjuvant durvalumab plus gemcitabine-cisplatin followed by adjuvant durvalumab after radical cystectomy for patients with muscle invasive bladder cancer.

The US FDA approved neoadjuvant...

03/31/2025

Oncology

FDA Approval

FDA Expands Approval of Lutetium Lu 177 Vipivotide Tetraxetan for Metastatic Castration-Resistant Prostate Cancer

03/28/2025

Stephanie Holland

Based on results from the PSMAfore trial, the FDA has expanded the approval of lutetium Lu 177 vipivotide tetraxetan to include patients with PSMA-positive metastatic castration-resistant prostate cancer previously treated with ARPIs and...

Based on results from the...

03/28/2025

Oncology

FDA Approval

FDA Approves Cabozantinib for Patients With Locally Advanced or Metastatic Well-Differentiated pNETs and epNETs

03/26/2025

Stephanie Holland

Based on results from the CABINET trial, the FDA has approved cabozantinib for patients 12 years of age and older with unresectable locally advanced or metastatic well-differentiated pNETs and epNETs who experienced disease progression after...

Based on results from the...

03/26/2025

Oncology